Achieve Life Sciences (QUIT) vs VolitionRX (VNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Achieve Life Sciences is the larger company by market cap ($573.2 million vs $5.8 million), about 98.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QUIT | VNRX |
|---|---|---|
| Share price | $5.56 | $0.1621 |
| Market cap | $573.25M | $5.85M |
| 1-day change | -5.28% | -1.58% |
| EPS (TTM) | $-1.71 | $-2.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73M |
| Revenue growth (YoY) | — | +40.04% |
| Net income (latest FY) | $-54.65M | $-23.36M |
| Operating margin | — | -1258.47% |
| Net margin | — | -1352.16% |
| 52-week high | $8.64 | $7.80 |
| 52-week low | $2.62 | $0.1555 |
| Distance from 52-week high | -35.65% | -97.92% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +162.23% | +8302.22% |
| Average volume | 1.38M | 9.57M |
| Shares outstanding | 103.10M | 36.08M |
| Employees | 28 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 98.0 times larger than VolitionRX by market value ($573.25M vs $5.85M).
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About VolitionRX
VNRX stock →VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 57 employees
QUIT vs VNRX FAQ
Which is bigger, Achieve Life Sciences or VolitionRX?
Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $5.85M for VolitionRX (VNRX).
Are Achieve Life Sciences and VolitionRX in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.